Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales
Hypothesis: The low-dose aspirin reduces cardiovascular risk in patients with chronic kidney disease without increasing the risk of bleeding
Age
45–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
sign informed consent
males 45-79 years or females 55-79 years. -Stage 3 or 4 CKD (estimated GFR by MDRD abbreviated, between 15 and 60 ml / min/1.73 m2) -
You may not be if
a previous cardiovascular event: cardiac arrhythmias, cardiac arrest, angina or acute myocardial infarction, stroke, carotid stenosis of more than 50%, peripheral vascular arteriopathy documented
hospitalization for any cause in the last three months prior to inclusion in the study allergy of acetyl-salicylic acid
coagulopathy from any cause
thrombocytopenia \<150,000 platelets
liver disease from any cause
Infection by hepatitis B virus, hepatitis C or HIV
immunosuppressive treatment within 12 weeks before inclusion in the study
Major bleeding events including gastrointestinal bleeding and brain hemorrhage.
hemoglobinopathies (eg sickle cell disease or thalassemia of any kind)
active malignancy (except non-melanoma skin cancer). May be included in the study patients with malignant neoplasia who have remained disease-free for at least the previous 5 years.
uncontrolled inflammatory disease or symptomatic (eg rheumatoid arthritis, lupus, Chrom disease or bowel inflammatory disease)
hemolysis
treatment with oral anticoagulation and / or antiplatelet therapy prior.
poorly controlled hypertension (\> 160/90 mm Hg) -pregnancy or breast-
women of childbearing potential not using effective contraception.
Clareo Health | Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients
